Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs ASP 2408 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Astellas Pharma; Maxygen
- 28 Apr 2014 Status changed from active not recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2011 New trial record